Dr. Jason A. Cantone

Jason A. Cantone, JD, PhD, is a senior research associate at the Federal Judicial Center (FJC). His work focuses on the use of science and technology in court proceedings, alternative dispute resolution (ADR), discovery in civil cases, and enhancing cooperation between state and federal courts. He has briefed international judges on topics including program evaluation, judicial competencies, mediation, and access to justice. In addition to his governmental work, Dr. Cantone publishes regularly in psychology and legal journals on topics such as reducing bias and discrimination and promoting effective legal decision-making processes. He also serves as an adjunct professor at George Mason University.

Dr. Kelly Dunn, M.B.A., M.S., Ph.D.

Education: M.B.A., Johns Hopkins Carey School of Business (Maryland) (2019); Ph.D., University of Vermont (Vermont) (2009); M.S., University of New Orleans (Louisiana) (2005); B.A., State University of New York (Oswego) (New York) (2002)

Additional Training: 2002, B.A. Philosophy, Oswego State University; 2013, Postdoctoral Fellowship in Behavioral Pharmacology, Johns Hopkins University School of Medicine

Professional: Associate Professor of Psychiatry and Behavioral

Research Summary

I have focused primarily on the treatment of opioid use disorder using human subjects. I have worked on more than 10 randomized clinical trial evaluations of treatments for patients with opioid use disorder, and have contributed to research regarding medication development for alcohol use disorder and cigarette smoking. I am currently pursing several lines of research regarding methods to enhance opioid treatment outcomes, to improve prevention of opioid overdose, to understand mechanisms underlying the development of opioid use disorder, to reduce concurrent problems among patients with opioid use disorder, and to develop tools for sensitively measuring overdose risk and noninjection drug use behavior with an emphasis on reducing HIV and HCV risk behaviors. Finally, I also have training in the use of incentives (contingency management) to modify behaviors.

More generally, I have expertise in human laboratory based studies of behavioral pharmacological techniques, clinical trial management and development, including FDA Good Clinical Practice procedures and guidelines, and secondary analyses of research projects with an emphasis on evaluating clinically-relevant outcomes.